Optimal management of pulmonary ground-glass opacity nodules

On the basis of the promising results of lung cancer screening in recent large trials, low-dose chest computed tomography (CT) has been widely introduced in clinical practice for the early detection of lung cancer (1,2). The increased use of CT for screening has also led to an increased detection of lung nodules, with a significant proportion of ground-glass opacity nodules (GGNs).